Clinical trial
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High…
NCT01968213 · pharmaand GmbH, Industry · Completed
Key facts
| NCT number | NCT01968213 |
|---|---|
| Title | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) |
| Official title | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 ) |
| Acronym | ARIEL3 |
| Lead sponsor | pharmaand GmbH, Industry |
| Collaborators | Foundation Medicine Industry Myriad Genetics, Inc. |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Rucaparib, Placebo |
| Enrollment | 564 |
| Start date | Apr 7, 2014 |
| Primary completion | Apr 1, 2017 |
| Completion | Jul 7, 2022 |
| First posted | Oct 23, 2013 |
| Last update posted | Jun 9, 2023 |
| Countries | Australia, Belgium, Canada, France, Germany, Israel, Italy, New Zealand, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: